Coya Therapeutics (NASDAQ:COYA) Given Buy Rating at Chardan Capital

Coya Therapeutics (NASDAQ:COYA)‘s stock had its “buy” rating reaffirmed by stock analysts at Chardan Capital in a note issued to investors on Tuesday,Benzinga reports. They currently have a $14.00 price objective on the stock. Chardan Capital’s target price suggests a potential upside of 143.90% from the stock’s previous close.

COYA has been the topic of several other research reports. D. Boral Capital reissued a “buy” rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research report on Tuesday, April 22nd. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Coya Therapeutics in a research report on Monday, June 9th. Finally, Wall Street Zen downgraded shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, May 22nd.

Coya Therapeutics Stock Down 0.2%

NASDAQ:COYA traded down $0.01 during trading hours on Tuesday, hitting $5.74. 24,834 shares of the company traded hands, compared to its average volume of 71,533. The company has a market cap of $96.03 million, a PE ratio of -5.36 and a beta of 0.22. The firm’s 50-day simple moving average is $5.87 and its 200-day simple moving average is $5.99. Coya Therapeutics has a one year low of $4.65 and a one year high of $10.24.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.44). The firm had revenue of $257.88 million for the quarter, compared to the consensus estimate of $2.63 million. As a group, equities research analysts expect that Coya Therapeutics will post -1.15 EPS for the current year.

Institutional Investors Weigh In On Coya Therapeutics

Several institutional investors have recently added to or reduced their stakes in COYA. Jane Street Group LLC raised its position in shares of Coya Therapeutics by 101.7% in the first quarter. Jane Street Group LLC now owns 26,137 shares of the company’s stock valued at $169,000 after purchasing an additional 13,176 shares during the period. Charles Schwab Investment Management Inc. bought a new stake in Coya Therapeutics during the 1st quarter valued at $65,000. CM Management LLC lifted its position in shares of Coya Therapeutics by 25.0% during the first quarter. CM Management LLC now owns 200,000 shares of the company’s stock worth $1,294,000 after acquiring an additional 40,000 shares in the last quarter. Dauntless Investment Group LLC bought a new position in shares of Coya Therapeutics in the first quarter worth $1,083,000. Finally, DME Capital Management LP boosted its stake in Coya Therapeutics by 29.2% in the 4th quarter. DME Capital Management LP now owns 1,646,440 shares of the company’s stock worth $9,434,000 after purchasing an additional 372,414 shares during the period. 39.75% of the stock is owned by hedge funds and other institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.